TITLE:
Acute Coronary Syndrome Occurring in a Sub-Saharan Patient Treated with a Reduced Dose of Sorafenib for an Unresectable Hepatocellular Carcinoma: Case Report
AUTHORS:
Antonin Wilson Ndjitoyap Ndam, Murielle Lema Helles, Pierre Mathurin Kowo, Mazou Temgoua Ngou, Etienne Atenguena, Blaise Mounpou, Aicha Yap, Tangie Ngek Larry, Paul Talla, Jerôme Boombhi, Alain Menanga, Firmin Ankouane Andoulo, Elie Claude Ndjitoyap Ndam
KEYWORDS:
Acute Coronorary Syndrome, Sorafenib, Hepatocellular Carcinoma, Hepatitis C Virus, Yaoundé
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.10 No.3,
March
12,
2020
ABSTRACT: Sorafenib is a chemotherapy used as first line treatment in primary liver cancers. It is an oral antiangiogenic treatment which reduces the progression of the tumor. Some mild or severe side effects have been reported among which some uncommon cardiac events: myocardial infarction and cardiogenic stroke. Sorafenib treatment remains expensive and not frequently used in Sub-Saharan countries. Thus, few studies have described its side effects in this milieu. We report a case of acute coronary syndrome occurring in a 75-year-old female patient, without cardiovascular risks factors, after nine months of sorafenib chemotherapy at a reduced dose for an unresectable hepatocellular carcinoma in a Sub-Saharan Africa country. The management was conducted by cardiologists, in collaboration with gastroenterologists and oncologists. We decided to completely stop sorafenib chemotherapy. We observed a reduction of the pain 48 hours after her admission, and a regression of electrocardiographic signs after 8 days. In conclusion, the sorafenib treatment can be associated with cardiac events despite the dose reduction.